Search

Your search keyword '"Seyed Alireza, Mahdaviani"' showing total 2 results
Start Over Author "Seyed Alireza, Mahdaviani" Journal clinical immunology
2 results on '"Seyed Alireza, Mahdaviani"'

1. Clinical, immunological, molecular and therapeutic findings in monogenic immune dysregulation diseases: Middle East and North Africa registry

Author

Mahnaz Jamee, Gholamreza Azizi, Safa Baris, Elif Karakoc-Aydiner, Ahmet Ozen, Sara Ş. Kiliç, Hulya Kose, Zahra Chavoshzadeh, Seyed Alireza Mahdaviani, Tooba Momen, Bibi Shahin Shamsian, Mazdak Fallahi, Samin Sharafian, Nesrin Gülez, Ayşe Aygun, Neslihan Edeer Karaca, Necil Kutukculer, Nashat Al Sukait, Tariq Al Farsi, Salem Al-Tamemi, Nisreen Khalifa, Reda Shereen, Dalia El-Ghoneimy, Rasha El-Owaidy, Nesrine Radwan, Raed Alzyoud, Mohamed-Ridha Barbouche, Imen Ben-Mustapha, Najla Mekki, Afef Rais, Rachida Boukari, Reda Belbouab, Kamel Djenouhat, Azzeddine Tahiat, Souad Touri, Gehad Elghazali, Suleiman Al-Hammadi, Hiba Mohammed Shendi, Amna Alkuwaiti, Brahim Belaid, Reda Djidjik, Hasibe Artac, Mehdi Adeli, Ali Sobh, Marwa H. Elnagdy, Sara A. Bahgat, Gulnara Nasrullayeva, Janet Chou, Nima Rezaei, Waleed Al-Herz, Raif S. Geha, Hassan Abolhassani, Seyed Erfan Rasouli, Marzie Esmaeili, Reza Yazdani, Samaneh Delavari, Marzieh Tavakol, Homa Sadri, Abdollah Karimi, Reza Shiari, Samin Alavi, Delara Babaie, Peyman Eshghi, Shahnaz Armin, Ahmad Vosughimotlagh, Sevgi Bilgic Eltan, Royala Babayeva, Asena Pinar Sefer, Burcu Kolukisa, Ezgi Yalcin Gungoren, Melek Yorgun Altunbas, and Vafa Mammadova

Subjects
Male, Primary immunodeficiency, Tunisia, Inborn-Errors, Adolescent, Turkey, Primary Immunodeficiency Diseases, Immunology, Vesicular Transport Proteins, Inborn errors of immunity, Autoimmune disorders, rab27 GTP-Binding Proteins, Lymphoproliferation, Immune dysregulation, Genetic, Child, Preschool, Humans, Immunology and Allergy, Egypt, Female, Registries, Child, Mutations, Adaptor Proteins, Signal Transducing, Retrospective Studies
Abstract

Monogenic immune dysregulation diseases (MIDD) are caused by defective immunotolerance. This study was designed to increase knowledge on the prevalence and spectrum of MIDDs, genetic patterns, and outcomes in Middle East and North Africa (MENA). MIDD patients from 11 MENA countries (Iran, Turkey, Kuwait, Oman, Algeria, Egypt, United Arab Emirates, Tunisia, Jordan, Qatar, and Azerbaijan) were retrospectively evaluated. 343 MIDD patients (58% males and 42% female) at a median (IQR) age of 101 (42-192) months were enrolled. The most common defective genes were LRBA (23.9%), LYST (8.2%), and RAB27A (7.9%). The most prevalent initial and overall manifestations were infections (32.2% and 75.1%), autoimmunity (18.6% and 41%), and organomegaly (13.3% and 53.8%), respectively. Treatments included immunoglobulin replacement therapy (53%), hematopoietic stem cell transplantation (HSCT) (14.3%), immunosuppressives (36.7%), and surgery (3.5%). Twenty-nine (59.2%) patients survived HSCT. Along with infectious complications, autoimmunity and organomegaly may be the initial or predominant manifestations of MIDD., Alborz University of Medical Sciences, This work was supported by the vice chancellor for research, Alborz University of Medical Sciences.

Published
2022
Full Text
View/download PDF

2. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin

Author

Mohammad Hossein Eslamian, Marzieh Tavakol, Alireza Shafiei, Seyed Alireza Mahdaviani, Nasrin Moazzen, Hossein Esmaeilzadeh, Ahmad Vosughi Motlagh, Narges Eslami, Mahnaz Sadeghi Shabestari, Nazanin Hosseini, Akefeh Ahmadiafshar, Hamid Ahanchian, Morteza Fallahpour, Zahra Chavoshzadeh, Mohammad Nabavi, Babak Shahhosseini, Hassan Abolhassani, Nasrin Khakbazanfard, Farzad Nazari, Mazdak Fallahi, Asghar Aghamohammadi, Taher Cheraghi, Arash Kalantari, Reza Yazdani, Sima Shokri, Mohammad Hassan Bemanian, Marzieh Heidarzadeh Arani, Mojgan Safari, Maryam Khoshkhui, Saba Arshi, Seyed Hesamedin Nabavizadeh, Negar Mortazavi, Sahar Samimi, Nima Rezaei, Aida Askarisarvestani, Afshin Shirkani, Pooria Nakhaei, Rasol Molatefi, and Soheila Aleyasin

Subjects
Adult, Male, myalgia, medicine.medical_specialty, Adolescent, Immunology, Cohort Studies, Ataxia Telangiectasia, Young Adult, Agammaglobulinemia, Immunity, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Immunology and Allergy, Child, Infusions, Intravenous, Adverse effect, Aged, Severe combined immunodeficiency, biology, business.industry, Immunologic Deficiency Syndromes, Immunoglobulins, Intravenous, Infant, Middle Aged, medicine.disease, Large cohort, Common Variable Immunodeficiency, Intravenous Immunoglobulins, Child, Preschool, biology.protein, Female, Chills, medicine.symptom, Antibody, business
Abstract

Background Intravenous immunoglobulins (IVIg) are the major treatment in inborn errors of immunity (IEI) disorders; However, IVIg infusions show some adverse effects. We aimed to assess the adverse reactions of IVIg infusions. Methods Data of IVIg infusions in IEI patients were collected from 2011 to 2021. Totally, 363 IEI patients received IVIg regularly in Iran entered the study. The adverse reactions are classified regarding their severity and chronicity. Results 22,667 IVIg infusions were performed in the study. 157 patients (43.2%) and 1349 (5.9%) infusions were associated with at least one type of adverse reaction. The highest rates of adverse reactions were seen in severe combined immunodeficiency. Myalgia, chills, headache, fever, and hypotension were the most frequent adverse effects of IVIg. Conclusion The reactions affect almost half of the patients mainly in the first infusions which necessitate the close observation of IEI patients receiving IVIg.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results